Proteome Sciences Share Discussion Threads

[barry evans] 22/1/2025 08:16

They are more likely considering 'downsizing'.

[peverill] 22/1/2025 08:03

Surely Mrs P is due a new kitchen??

[monte1] 21/1/2025 10:58

It was bloody great while it lasted though.

[peverill] 21/1/2025 10:22

Is that it till June??

[barry evans] 20/1/2025 14:40

I note that the clown appears to have 'moved on'.

[elpirata] 16/1/2025 14:04

prm dont buy Thermo Exploris machines, they cost $975,000, they lease them on the 3 yearly renewal cycle to avoid obsolescence, hence the careful rns wording...'to facilitate the acquisition'

Technological advances in Mass Spectrometry occur on average every 18 months. Technology Refresh helps safeguard against analytical instrument obsolescence by offering financing for a new mass spectrometer with a 36-month operating lease, fixed monthly payments, and the option to upgrade to the latest available technology at the 24th month of the term.

The program applies to new acquisitions, but can be modified for trade-ins and replacements for current aging equipment. For more information, contact the Thermo Fisher Financial Services team at [phone].

[peverill] 16/1/2025 13:51

And everything back to normal,just an extra million in debt,can someone let CJP know it's a busted flush and not worth throwing more money at.

[monte1] 16/1/2025 09:10

Good lord.

What madness is this?

[suffolkhath] 15/1/2025 01:22

>54 At this stage I'd like to help Jeffian out.
Show us the money. Go on, show us the money.

[z1co] 13/1/2025 12:20

In auction on only about 71,000 buys !

Looking good to breach 5p today.

[wasjobber] 13/1/2025 11:41

Z1CO,

I personally think it will have to be much higher than that.

Proteome Sciences are in a particularly sweet spot with what they have tucked away!

[z1co] 13/1/2025 11:40

Launch of world’s most significant protein study set to usher in new understanding for medicine

January 10th 2025

UK Biobank has today announced the launch of the world’s most comprehensive study of the proteins circulating in our bodies, which will transform the study of diseases and their treatments. This unparalleled project aspires to measure up to 5,400 proteins in each of 600,000 samples, including those taken from half a million UK Biobank participants and 100,000 second samples taken from these volunteers up to 15 years later. This will allow researchers to explore a first-of-its-kind database, detailing how changes to an individual’s protein levels over mid-to-late life influence disease. The study will begin by analysing the first 300,000 samples, which will include initial samples from 250,000 UK Biobank volunteers and 50,000 second samples taken at follow-up assessments.

Measuring the abundance of thousands of proteins circulating in the blood enables researchers to investigate their potential role in many types of diseases that occur during mid-to-late life. This emerging research field – known as population proteomics – has demonstrated huge potential for diagnostics and therapeutics.

In October 2023, a pilot project released data on nearly 3,000 circulating proteins from 54,000 UK Biobank participants. The pilot was already the world’s largest study of its kind and led to research identifying over 14,000 links between common genetic variants and altered protein levels, over 80% of which were previously unknown.

The research, published in Nature (1), has already been cited over 400 times, laying the foundations for scientists to better understand how and why diseases develop. So far, studies using the data have led to advances in disease prediction (2),(3) and developing future targeted treatments for breast cancer (4), cardiovascular disease (5), Parkinson’s disease (6), and other brain illnesses (7).  

This new study, which aims to increase this unique dataset by ten-fold, is being funded by a consortium of 14 leading biopharmaceutical companies, known as the UK Biobank Pharma Proteomics Project.   

"For the first time at this scale, researchers will be able to detect the exact causes of diseases by comparing how protein levels change over mid-to-late life in a large group of people. Proteomic data has already paved the way for better cancer, autoimmune and dementia diagnostics, and this truly exciting study of proteins will significantly speed up drug discovery, leading to major improvements in public health and care everywhere."
Professor Sir Rory Collins, Principal Investigator and Chief Executive, UK Biobank

"UK Biobank is an extraordinary resource for medical research and has already had a big impact on diagnosis and treatments. The plan to study proteins in participants across the study has the potential to unlock a new era of possibilities.  That this is being funded by a wide consortium of companies highlights the importance of pre-competitive research to increase knowledge for everyone who is trying to be innovative to improve health."
Lord Patrick Vallance, Minister of State for Science, Research and Innovation of the United Kingdom

UK Biobank’s proteomics dataset will allow researchers to: 

Examine proteomic and genetic data from half a million people simultaneously. UK Biobank released the whole genome sequencing of its half a million participants in November 2023. Adding proteomic data will allow researchers to combine these massive datasets, providing a more detailed picture of the biological processes involved in disease progression. This may in turn drive the development of personalised treatments.
Examine how and why protein levels change over time. Half a million participants provided UK Biobank with a blood sample when they joined and 100,000 of them provided a second sample up to 15 years later. Researchers will be able to see how protein levels have changed over mid-to-late life, enhancing understanding of age-related changes in healthy individuals and shedding light on how diseases develop. This will further accelerate research into diagnostic and prognostic markers.
Uniquely use proteomic data in combination with imaging data. Nearly 100,000 UK Biobank participants have undergone magnetic resonance imaging (MRI) of their brain, heart and body, providing researchers with detailed scans. Layering these different data types to investigate human health creates a truly extraordinary, detailed understanding of the disease mechanisms.
Open avenues for developing AI models. Already, machine learning tools can predict future disease many years before diagnosis, with the potential to shape early interventions (8). The depth and breadth of the proteomic data held within UK Biobank may enable machine learning to accurately subtype diseases, which has the potential to inform what treatments should be given at the point of diagnosis.
"Proteomics provides an incredibly detailed snapshot of health. This new frontier of science can unveil how genetics and external factors – like diet, exercise and climate – interact, and will help to pinpoint the key causes of diseases and identify drug targets. It has already led to important scientific discoveries, such as identifying proteins that can help to diagnose disease – including multiple sclerosis (9) – and helping to identify those at higher risk of developing dementia (10) and cancer (11) many years before clinical diagnosis. Over 19,000 researchers around the world are using UK Biobank data; adding proteomic data to everything else we hold will enable scientists to make rapid discoveries to help diagnose and treat life-altering diseases.”"

[z1co] 13/1/2025 11:37

Any bid has to be in the region of £100m to fully reflect the value of PRM.

[wasjobber] 13/1/2025 11:30

Z1CO thanks

It's not difficult to see a number of global players wanting to buy Proteome Sciences. PRM have many valuable patents / technology to offer and it's all very scalable to one of the big boys!

[z1co] 13/1/2025 11:22

Thnx , wasjobber

Difficult to answer that question.

The company will be in a period of substantial growth which started in the 2nd half of last year , the share price increase is beginning to reflect this growth.

We will see record revenue and profits from 2025 onwards , the share price will RISE many FOLDS from the current levels over the next few years.

[wasjobber] 13/1/2025 11:11

Z1CO,

Thanks for all of your recent posts.

How long before PRM is taken over?

[z1co] 13/1/2025 11:00

Pharma firms team up to study UK proteomics data

Largest proteomic study to date launched by consortium of 14 drug companies

by Laura Howes
January 10, 2025

[z1co] 13/1/2025 09:17

suffolkhath/mashman

That's a subtle deramp !

btw your buys in December 2003 must have been around £2 at the all time highs.

[goatherd] 13/1/2025 07:56

Please chutes, that would be lovely.

I seem to remember it was called the "five pound party".

Those were the days.